Featured
< Back to NewsApril 22, 2024
Recent Changes to the Federal Rules of Evidence Governing the Admissibility of Expert Testimony Effective December 1, 2023, the Federal Rules of Evidence relating to the admissibility of expert testimony were amended. The Federal Advisory Committee on Evidence Rules (the “Committee”) indicated that Rule 702 (Testimony by Expert Witness) was amended in order to clarify... Read More
January 19, 2024
Federal Circuit Affirms Use of Skinny Label for Vortioxetine In December 2023, the United States Court of Appeals for the Federal Circuit affirmed a district court’s opinion regarding noninfringement of two patents related to specific uses of the antidepressant drug Trintellix® (vortioxetine). This opinion reaffirmed the use of the “section viii” statement, allowing companies... Read More
October 2, 2023
Delaware Chief Judge Connolly Credits Ivan Hofmann’s Commercial Success Testimony in a Pharmaceutical Patent Case Gleason IP was retained by multiple defendants in a patent infringement matter related to Taiho Pharmaceutical Co., Ltd. and Taiho Oncology, Inc.’s Lonsurf® (trifluridine and tipiracil) tablets. Lonsurf® tablets are a prescription medicine for stomach cancer (sometimes referred to... Read More
July 20, 2023
Federal Circuit Affirms the Use of Blocking Patents in a Commercial Success Inquiry In the patent litigation between UCB and Actavis related to the reformulated Neupro® patch, the Federal Circuit affirmed the District Court’s decision regarding Ivan Hofmann’s testimony related to blocking patents that dissuaded competitors from developing a rotigotine patch that practiced the claimed... Read More